This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the a? heterodimer.¹⁹

Additional reported applications (for the relevant formats) include: immunoprecipitation⁸, Western blotting⁸, in vitro blocking of mixed lymphocyte reactions^9,10, depeletion of MHC class II cells⁷,?immunohistochemical staining of acetone-fixed frozen sections^4,5, and spatial biology (IBEX)^21,22. For sensitive functional assays, we recommend using the Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) (Cat. No. 307648, 307665 - 307669).

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Brodsky F. 1984. Immunogenetics 19:179.
2. Robbins P, et al. 1987. Human Immunol. 18:301.
3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
6. Zipf T, et al. 1981. Cancer Res. 41:4786.
7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
10. Wang RF, et al. 1999. Science 284:1351. (Block)
11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
19. Moro M, et al. 2005. BMC Immunol. 6:24.
20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
21. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
22. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed

1. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
2. Arunachalam PS, et al. 2021. Nature. 596:410. PubMed
3. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
4. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
5. Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed
6. NULL, et al. 2022. Cell. 185:916. PubMed
7. Kennedy-Darling J, et al. 2021. Eur J Immunol. 51:1262. PubMed
8. Wimmers F, et al. 2021. Cell. 184:3915. PubMed
9. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
10. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed

B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.